Recombinant TNFRSF10B (Drozitumab Biosimilar) antibody

Catalog No. ABIN7795105

The Mouse Monoclonal anti-TNFRSF10B (Drozitumab Biosimilar) antibody (ABIN7795105) specifically detects TNFRSF10B (Drozitumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant TNFRSF10B (Drozitumab Biosimilar) antibody (ABIN7795105)

Target: TNFRSF10B (Drozitumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TNFRSF10B (Drozitumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-TNFRSF10B (Drozitumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Drozitumab Biosimilar, TRAIL Monoclonal Antibody

Characteristics: Drozitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab. Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human TRAIL

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for TNFRSF10B (Drozitumab Biosimilar)

Target: TNFRSF10B (Drozitumab Biosimilar)

Alternative Name: Drozitumab Biosimilar

Target Type: Biosimilar